Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
 Announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Feb. 10, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Arizona on behalf of certain purchasers of shares of Insys Therapeutics Inc (NASDAQ:INSY) over alleged Securities Laws Violations by Insys Therapeutics.
Investors who purchased shares of Insys Therapeutics Inc (NASDAQ:INSY) have certain options and for certain investors are short and strict deadlines running. Deadline: April 4, 2016. NASDAQ:INSY investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff claims that the defendants are alleged to have failed to disclose that the Company was engaged in the illegal and improper off-labeling marketing of Subsys, that certain Insys employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys, and that as a result, the Company's financial statements were materially false and misleading at all relevant times.
On April 24, 2015, an article was published entitled "Insys Therapeutics and the New 'Killing It,'" reporting on patients who either died or suffered adverse events while being treated with Subsys. The article also detailed how Insys Therapeutics Inc aggressively markets Subsys.
On May 20, 2015, another article was published entitled "Top prescribers of Insys Therapeutics' Subsys arrested on drug charges," reporting that two of Insys's highest-volume prescribers had been charged with illegal prescription drug distribution by the Drug Enforcement Agency ("DEA").
On June 25, 2015, another article reported that a nurse in Connecticut pled guilty to participating in a kickback scheme wherein she accepted approximately $83,000 in kickbacks from Insys Therapeutics Inc in exchange for writing more than $1 million worth of Subsys prescriptions.
On December 3, 2015, another article was published entitled "Murder Incorporated: Insys Therapeutics, Part I," alleging that one Defendant had been forced to resign from the Company by Insys Therapeutics’ founder and the Executive Chairman of Insys's Board of Directors—and that Insys Therapeutics Inc operated a scheme to promote the illegal and improper off-label marketing and sale of Subsys.
On January 25, 2016, another article was published entitled "The Brotherhood of Thieves: Insys Therapeutics," alleging that Insys Therapeutics' executives have continued to pressure Company employees to develop new schemes to promote the illegal and improper off-label marketing and sale of Subsys.
Those who purchased NASDAQ:INSY shares should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
